Publication | Closed Access

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Advanced Breast CancerBreast OncologyOncologyMedicineGynecologyBreast CancerPharmacotherapyMenopauseMenopause Hormone TherapyCancer TreatmentPharmacologyMtor InhibitionEndocrine-related CancerPostmenopausal Women